Description:
A proof of concept clinical trial to assess the synergism of curcumin (CURC) and ursolic acid
(UA). Before further testing within formal cancer clinical trials, we must (1) evaluate the
bioavailability and safety, (2) confirm the presence of metabolites in the target organ, and
(3) validate the appropriate mechanism of effect
Title
- Brief Title: Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate
- Official Title: Phase I Clinical Trial Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate
Clinical Trial IDs
- ORG STUDY ID:
HSC20190735H
- NCT ID:
NCT04403568
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Ursolic Acid | | Ursolic Acid |
Curcumin | | Curcumin |
Purpose
A proof of concept clinical trial to assess the synergism of curcumin (CURC) and ursolic acid
(UA). Before further testing within formal cancer clinical trials, we must (1) evaluate the
bioavailability and safety, (2) confirm the presence of metabolites in the target organ, and
(3) validate the appropriate mechanism of effect
Detailed Description
Once a subject is identified that may meet eligibility criteria, the physician and/or study
investigators will be alerted to the potential candidate and will introduce the study to the
patient at their standard of care (SOC) appointment or via telephone. Patients will be given
the option for enrollment and if they agree, informed consent will be discussed and obtained
provided they meet all inclusion/exclusion criteria. Following informed consent, subjects
will be assigned to one of the following cohorts:
Cohort 1:
• Ursolic Acid (150 mg) BID (twice a day)
Cohort 2:
• Curcumin (600 mg) BID
Cohort 3:
• Ursolic Acid (150 mg) and Curcumin (600 mg) BID
The study team aim to enroll 10 subjects who will complete the study into each cohort for a
total of 30 completers. Subjects will be enrolled on a rolling basis with the first ten
subjects assigned to Cohort 1, the next ten subjects assigned to Cohort 2, and the last 10
subjects assigned to Cohort 3.
Trial Arms
Name | Type | Description | Interventions |
---|
Ursolic Acid | Experimental | Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy | |
Curcumin | Experimental | Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy | |
Ursolic Acid and Curcumin | Experimental | Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy | |
Eligibility Criteria
Inclusion Criteria:
- Have proven diagnosis of prostate cancer with Gleason Group 3 or lower and planning to
undergo radical prostatectomy
- Be able to give informed consent
- Be age 18 or older
- Able to stop supplements
Exclusion Criteria:
- Unable to give informed consent
- Age < 18
- High-risk prostate cancer or suspected metastasis
- Unable to swallow pills
- Unable to stop supplements
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | Male |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Number, frequency, duration, and relation of toxicity events |
Time Frame: | Baseline to 8 weeks |
Safety Issue: | |
Description: | Safety will be compared to evaluate the number, frequency, duration, and relation of toxicity events to CURC/UA combination, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03. |
Secondary Outcome Measures
Measure: | Levels of UA, CURC, and metabolites in prostate tissue |
Time Frame: | Baseline to 8 weeks |
Safety Issue: | |
Description: | Identify the presence and levels of UA, CURC and their metabolites in prostate tissue using HPLC. |
Measure: | Immunohistochemistry measurement |
Time Frame: | Baseline to 8 weeks |
Safety Issue: | |
Description: | Immunohistochemistry of proportion of nuclear p65 NFkB staining before and after prostatectomy on FFPE samples will be completed. |
Details
Phase: | Early Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Not yet recruiting |
Lead Sponsor: | The University of Texas Health Science Center at San Antonio |
Trial Keywords
Last Updated
June 23, 2021